Loading...
Loading...
ACLX| Name | Value |
|---|---|
| Revenues | 15.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 15.3M |
| Operating Expense | 68.4M |
| Operating I/L | -53.2M |
| Other Income/Expense | 7.6M |
| Interest Income | 7.6M |
| Pretax | -45.6M |
| Income Tax Expense | 1.5M |
| Net Income/Loss | -47.1M |
Arcellx, Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapies for cancer and other incurable diseases. The company's lead product candidate, CART-ddBCMA, is in phase 1 clinical trial for treating relapsed or refractory multiple myeloma. Additionally, Arcellx is developing ACLX-001, an immunotherapeutic combination targeting BCMA for the treatment of multiple myeloma, as well as ACLX-002 and ACLX-003 for r/r acute myeloid leukemia and myelodysplastic syndrome. The company also has solid tumor programs in its pipeline.
